Chemours (CC) EBITDA (2014 - 2026)

Chemours' EBITDA history runs 13 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• On a quarterly basis, EBITDA fell 50.94% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was -$90.0 million, a 134.88% decrease from a year earlier, with the FY2025 full-year figure at -$64.0 million, down 120.06% from the prior year.
• EBITDA rose to $26.0 million in Q1 2026 per CC's latest filing, from -$5.0 million in the prior quarter.
• Across five years, EBITDA topped out at $304.0 million in Q1 2022 and bottomed at -$396.0 million in Q2 2023.
• The 5-year median for EBITDA is $53.0 million (2025), against an average of $47.6 million.
• Across the five-year window, EBITDA tumbled 282.49% in 2023 and soared 1116.67% in 2024, its largest moves.
• Year by year, EBITDA stood at -$9.0 million in 2022, then surged by 33.33% to -$6.0 million in 2023, then surged by 1116.67% to $61.0 million in 2024, then tumbled by 108.2% to -$5.0 million in 2025, then jumped by 620.0% to $26.0 million in 2026.
• Per Business Quant, the three latest CC EBITDA figures stand at $26.0 million (Q1 2026), -$5.0 million (Q4 2025), and $81.0 million (Q3 2025).